Mechanisms of Compound Kushen Injection for the Treatment of Lung Cancer Based on Network Pharmacology

Ziqi Meng,1 Xinkui Liu,1 Jiarui Wu,1 Wei Zhou,1 Kaihuan Wang,1 Zhiwei Jing,2 Shuyu Liu,1 Mengwei Ni,1 and Xiaomeng Zhang1

1Department of Clinical Chinese Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102, China
2Department of Academic Management, China Academy of Chinese Medicine Sciences, Beijing 100700, China

Correspondence should be addressed to Jiarui Wu; exogamy@163.com

Received 20 January 2019; Revised 23 April 2019; Accepted 20 May 2019; Published 28 May 2019

Academic Editor: Laura De Martino

Copyright © 2019 Ziqi Meng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Compound Kushen Injection (CKI) is a Chinese patent drug that shows good efficacy in treating lung cancer (LC). However, its underlying mechanisms need to be further clarified. Methods. In this study, we adopted a network pharmacology method to gather compounds, predict targets, construct networks, and analyze biological functions and pathways. Moreover, molecular docking simulation was employed to assess the binding potential of selected target-compound pairs. Results. Four networks were established, including the compound-putative target network, protein-protein interaction (PPI) network of LC targets, compound-LC target network, and herb-compound-target-pathway network. Network analysis showed that 8 targets (CHRNA3, DRD2, PRKCA, CDK1, CDK2, CHRNA5, MMP1, and MMP9) may be the therapeutic targets of CKI in LC. In addition, molecular docking simulation indicated that CHRNA3, DRD2, PRKCA, CDK1, CDK2, MMP1, and MMP9 had good binding activity with the corresponding compounds. Furthermore, enrichment analysis indicated that CKI might exert a therapeutic role in LC by regulating some important pathways, namely, pathways in cancer, proteoglycans in cancer, PI3K-Akt signaling pathway, non-small-cell lung cancer, and small cell lung cancer. Conclusions. This study validated and predicted the mechanism of CKI in treating LC. Additionally, this study provides a good foundation for further experimental studies and promotes the reasonable application of CKI in the clinical treatment of LC.

1. Introduction

Lung cancer (LC) has become an important etiology of malignant mortality worldwide [1]. Approximately 1.37 million deaths annually worldwide have been attributed to LC, and LC is a significant cause of cancer-related deaths in China [2, 3]. LC is divided into several different categories, such as lung adenocarcinoma, squamous cell lung carcinoma, large cell carcinoma and small cell lung carcinoma (SCLC) [4]. Current treatment strategies for LC include surgery, chemotherapy, radiation therapy, laser therapy, and photodynamic therapy [5–7]. The most important therapeutic tactic for LC is chemotherapy, but invasion and metastasis of LC cells often occur after chemotherapy [8].

Because traditional Chinese medicine (TCM) can alleviate uncomfortable symptoms, improve survival benefits, and reduce the side effects of chemotherapy, TCM has become one of the crucial options for comprehensive cancer treatments [9, 10]. Compound Kushen Injection (CKI, also known as Yanshu injection) is a TCM preparation derived from two herbs, kushen (Radix Sophorae Flavescentis), and baituling (Rhizoma Smilacis Glabrae) [11, 12]. Matrine and oxymatrine are the primary active compounds in CKI and have antitumor effects in different cancer cells, including breast cancer cell lines (MCF-7), gastric cancer cells (SGC-7901 and MKN45), and human liver cancer cells (SMMC-7721) [13, 14]. Many clinical studies have confirmed that CKI can be used to treat malignant tumors by inducing apoptosis in tumor cells, as well as by inhibiting cancer cell proliferation and tumor growth, migration and invasion [13, 15, 16]. Moreover, a recent study has systematically investigated the mechanism of CKI in treating hepatocellular
carcinoma based on a network pharmacology method [17]. Additionally, CKI also synergizes the curative effects of radiotherapy and chemotherapy for cancer patients as well as mitigates radiotherapy and chemotherapy toxic side effects [18, 19]. In particular, CKI relieves the pain of cancer patients, which is of great significance to improve their quality of life and prolong their survival [20, 21].

TCM serves as a multicomponent, multitarget, and multipathway therapy that acquires its special treatment efficacy by acting on the biological network of body systems, and thereby, it is difficult to elucidate the mechanisms of TCM [22, 23]. Fortunately, network pharmacology provides a new perspective for promoting a new understanding of the mechanisms of drugs [24, 25]. Network pharmacology updates the “one target, one drug” model to the “multicomponent, multitarget” model and better elucidates the complex interactions among genes, proteins, and metabolites associated with diseases and drugs from a network perspective [26, 27].

Although several studies have indicated that CKI has efficacy in the treatment of LC [28–30], its molecular mechanisms have not been completely elucidated. Therefore, our study adopted the network pharmacology method to better investigate and predict the molecular mechanism of CKI against LC. A detailed flowchart of the network pharmacology-based study is shown in Figure 1.

2. Materials and Methods

2.1. Chemical Components of CKI. After searching the literature [31, 32], 23 compounds of CKI were selected to further study. We inputted all the compounds into the PubChem database [33] (https://pubchem.ncbi.nlm.nih.gov), and then removed the compounds with duplicated data and without structural information. In total, 16 chemical components were collected and these compounds were clustered by K-means clustering algorithm based on their molecular descriptors.

2.2. Putative Targets of CKI. The simplified molecular input entry specification (SMILES) information of 16 compounds was imported into the Search Tool for Interacting Chemicals (STITCH), SuperPred, and SwissTargetPrediction databases. STITCH [34] (http://stitch.embl.de/) is a database of known and predicted interactions between compounds and proteins, and the database is based on text mining and molecular docking techniques to predict interactions between compounds and proteins. STITCH has been used to study TCM to find the potential active components and to explain the molecular mechanism of TCM [35]. The SuperPred database [36] (http://prediction.charite.de/) is based on the principle of similarity that links the chemical similarity of drug-like compounds to molecular targets and the therapeutic approach. SwissTargetPrediction [37] (http://www.swisstargetprediction.ch/) is a web server based on chemical similarity that can accurately predict bioactive molecular targets. Finally, we obtained corresponding targets after discarding duplicate data.

2.3. LC Targets. Different genes related to LC were gathered from the Therapeutic Target Database (TTD, https://db.idrblab.org/ttd/), which is a database that provides information about nucleic acid targets and therapeutic effects of proteins [38], and the Online Mendelian Inheritance in Man [39] (OMIM, http://www.omim.org/), which is an online database of continuously updated human genes and genetic diseases. The keyword “lung cancer” was used in the TTD and OMIM databases to search for LC-related targets.

2.4. Protein-Protein Interaction Data. Protein-protein interaction (PPI) data were extracted from Search Tool for the Retrieval of Interacting Genes/Proteins (STRING, https://string-db.org/). STRING is a database of known and predicted PPIs, including both direct and indirect interactions among proteins [40]. STRING defines PPIs with confidence ranges for data scores (low: <0.4; medium: 0.4 to 0.7; high: >0.7). We inputted the LC-related targets into the STRING database, with the species limited to “Homo sapiens” and the confidence scores higher than 0.7.

2.5. Network Construction. We constructed four networks in this study as follows: (1) a compound-putative target network was established by linking chemical compounds of CKI and corresponding targets; (2) the PPI network of LC targets was built by connecting LC-related targets and other human proteins that linked or interacted with LC targets; (3) a compound-LC target network was constructed by intersecting the compound-putative target network and the PPI network of LC targets. The genes that did not intersect were removed; namely, the common targets between the compound-putative target network and the PPI network of LC targets were the potential targets for the ingredients of CKI in LC; and (4) an herb-compound-target-pathway network was built by linking herbs, compounds, corresponding targets, and pathways.

Cytoscape 3.5.1 software [41] (http://www.cytoscape.org/) was used to construct all of the above networks. Cytoscape is bioinformatics analysis software that is applied to visual biological pathways and intermolecular interaction networks. Cytoscape provides a set of basic data integration, analysis, and visualization functions to analyze complex networks. For each node in the interaction network, a significant parameter “Degree” is calculated to evaluate its topological features. A degree is defined as the number of edges to node i [41, 42]. The higher the degree is, the more important the node is.

2.6. Molecular Docking Simulation. SystemsDock [43] (http://systemsdock.unit.oist.jp/iddp/home/index) is an emerging web server for network pharmacology-based prediction and analysis and illustrates the mechanism of ligand acting on a complex molecular network by applying high-precision docking simulation and molecular pathway map. The docking score of systemsDock is a negative logarithm of the experimental dissociation/inhibition constant (pKd/pKi), which can directly indicate the binding strength [44]. We used systemsDock to evaluate the binding potential between selected targets and corresponding compounds in the compound-LC target network.

2.7. Gene Ontology and Pathway Enrichment. To illustrate the role of potential targets in gene function and signal pathways,
Figure 1: Flowchart for CKI in treating LC.
we used the Database for Annotation, Visualization and Inte-
gerated Discovery [45] (DAVID, https://david.ncifcrf.gov/) to
perform Gene Ontology (GO) function enrichment analysis
and Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway enrichment analysis of genes in the compound-LC
target network.

3. Results

3.1. Compound-Putative Target Network. The details of the
16 compounds in CKI are described in Supplementary Table
S1. And these compounds were clustered into 5 clusters
(Figure 2). As shown in Figure 3, the compound-putative
target network included 196 nodes (16 compound nodes and
180 putative target nodes) and 326 edges. In this network,
many putative targets were regulated by multiple compounds.
For example, CHRNA4 and CHRNB2 were modulated by
matrine, oxymatrine, and so on. In addition, network analysis
showed that the average degree value of compounds was
20.38, indicating the properties of multitargets of CKI in
treating LC. Notably, there were 3 compounds with degree
≥ 20.38, namely, adenine (degree = 72), matrine (degree
= 21), and oxymatrine (degree = 21), demonstrating their
significance in the network.

3.2. PPI Network of LC Targets. A total of 97 LC targets
were retrieved from the TTD and OMIM databases (as shown in
Supplementary Table S2). In Figure 4, the PPI network of LC
targets was composed of 188 LC-related genes and 2019 LC-
associated PPIs. Three topological features of each node in
the network were calculated to find the major nodes. Ultimately,
26 nodes with an average degree value ≥ 21.48, betweenness ≥
0.01251 and closeness ≥ 0.4547 were selected as major nodes
(the details about the information of 26 nodes are described
in Supplementary Table S3). Therefore, these genes might be
the key genes in the development of LC.

3.3. Compound-LC Target Network. The compound-LC tar-
gent network is shown in Figure 5 and includes 39 nodes (12
compound nodes and 27 target nodes) and 41 edges. The
network showed that the 27 notes might serve as potential
targets of CKI for treating LC (Supplementary Table S4). To
find the major nodes, we selected 8 targets based on
an average value of degree ≥ 1.52, namely, neuronal acetyl-
choline receptor subunit alpha-3 (CHRNA3), D(2) dopamine
receptor (DRD2), protein kinase C alpha type (PRKCA),
cyclin-dependent kinase 1 (CDK1), cyclin-dependent kinase
2 (CDK2), neuronal acetylcholine receptor subunit alpha-
5 (CHRNA5), interstitial collagenase (MMP1), and matrix
metalloproteinase-9 (MMP9), indicating that they were likely
to be potential targets of CKI for the treatment of LC. In
addition, 6 compounds were selected with degree ≥ 3, such as
adenine, macrozamin, matrine, oxymatrine, baptifoline, and
N-methylcytisine, illustrating that these compounds were
likely to be key compounds of CKI in treatment for LC.

3.4. Molecular Docking Verification. The 3D structures of the
above 8 selected targets were gathered from the PDB database
[46] (https://www.rcsb.org/), which is the single global
archive and includes experimentally determined atomic-level
3D structures of biological macromolecules (proteins, DNA,
and RNA). The results showed that 7 targets (CHRNA3,
3.5. GO and Pathway Enrichment Analysis. To elucidate the multiple mechanisms of CKI on LC from a systematic level, we performed GO enrichment analysis for 27 targets of the compound-CKI target network. In total, 16 enriched GO terms were identified (FDR < 0.01, as shown in Figure 7). For biological processes, the targets of CKI were enriched in protein phosphorylation (GO:0006468), positive regulation of ERK1 and ERK2 cascade (GO:0070374), G1/S transition of mitotic cell cycle (GO:0000082), positive regulation of gene expression (GO:0010628), ERBB2 signaling pathway (GO:0038128), protein kinase activity (GO:0004672), and regulation of phosphatidylinositol 3-kinase signaling (GO:0014066). Protein kinase activity (GO:0004672), protein serine/threonine kinase activity (GO:0004674), ATP binding (0005524), cyclin-dependent protein serine/threonine kinase activity (GO:0004693), kinase activity (GO:0016301), and cyclin binding (GO:0030332) were the particularly enriched molecular functions. For cellular components, the targets of CKI were enriched in cyclin-dependent protein kinase holoenzyme complex (GO:0000307).

To illustrate the crucial pathways among the 27 potential targets in LC treatment, we screened 22 pathways according to FDR < 0.01 (as shown in Figure 8), including proteoglycans in cancer (hsa05205), non-small-cell lung cancer (hsa05223), pathways in cancer (hsa05200), glioma (hsa05214), bladder cancer (hsa05219), prostate cancer (hsa05215), pancreatic cancer (hsa05212), melanoma (hsa05218), endometrial cancer (hsa05213), chronic myeloid leukemia (hsa05220), small cell lung cancer (hsa05222), FoxO signaling pathway (hsa04068), focal adhesion (hsa04510), progesterone-mediated oocyte maturation (hsa04914), estrogen signaling pathway (hsa04915), p53 signaling pathway (hsa04115), rap1 signaling pathway (hsa04015), hepatitis B (hsa05161), PI3K-Akt signaling pathway (hsa04151), measles (hsa05162), ErbB signaling pathway (hsa04012), and HIF-1 signaling pathway (hsa04066). Finally, based on the above information, we constructed an herb-compound-target-pathway network (Figure 9) to holistically explain the mechanism of CKI in treating LC.

4. Discussion

CKI has been clinically used to treat various types of solid tumors [48]. Currently, CKI has been widely used...
for pain treatment in combination with chemotherapy and radiotherapy throughout China [49]. In the present work, we constructed a compound-putative target network, PPI network of LC targets, compound-LC target network, and herb-compound-target-pathway network to systematically analyze the mechanism of CKI in the treatment of LC.

In the compound-putative target network, adenine, matrine, and oxymatrine were recognized as significant compounds. Adenine was shown to be associated with a variety of LC targets, including CDK1, CDK2, MMP1, MMP9, and so on. Matrine is widely known as the main chemical composition of CKI and matrine derivatives containing the benzo-α-pyrones structure are potent antilung cancer agents [50]. A recent study indicated that matrine inhibits the migration and invasion of non-small-cell lung cancer (NSCLC) cells by interfering with the epithelial-mesenchymal transition signaling pathway [51]. Moreover, the matrine derivative YF-18 inhibits the growth and migration of LC cells by inducing G2/M cell cycle arrest and downregulating Skp2 [52]. The present research found that matrine was associated with some LC-related targets, including MMP9, CHRNA3, and CCND1. Moreover, previous studies have also demonstrated that oxymatrine has anticancer potential in various types of cancer cells by multiple mechanisms [55–57]. Furthermore, a relevant report implied that oxymatrine inhibits NSCLC by suppressing the activity of the EGFR signaling pathway [58]. In addition, oxymatrine has been proven to be a restrainer of TLR2 and TLR4 and an agonist of MMP1 [59, 60]. Fortunately, our current study also discovered that oxymatrine interacted with the above three LC-related targets. However, some results of our study have been rarely reported, and thus, further studies are urgently needed to validate our results.

In the PPI network of LC targets, TP53, PCNA, CDK1, and CDK2, which possessed high values for degree, betweenness, and closeness, were selected as major nodes. TP53 is a significant tumor suppressor gene that is closely related to the cell cycle, proliferation, differentiation, aging, and apoptosis [61]. Meanwhile, gene alteration of TP53 is associated with a poor prognosis in patients with NSCLC [62]. PCNA is a key eukaryotic replication accessory factor that plays an important role in the cell cycle and apoptosis [63]. In addition, PCNA can promote LC progression [64]. CDK1 and CDK2 belong to the cyclin-dependent kinases (CDKs) family. CDKs are a specific family of enzymes that turn on cell cycle mechanisms. CDKs require association with regulatory proteins (cyclins), and the absence of regulatory proteins at cell cycle checkpoints leads to carcinogenesis or
Evidence-Based Complementary and Alternative Medicine

Figure 5: Compound-LC target network. Yellow octagons represent compounds in CKI. Red circles represent potential targets for CKI in the treatment of LC. There is a positive proportional relationship between the node size and the degree.

The compound-LC target network included 27 targets, and these targets mainly act on adenine, macrozamin, matrine, oxymatrine, baptifoline, and N-methylcytisine. The 8 targets with a degree ≥ 1.52 were determined as key targets, including CHRNA3, DRD2, PRKCA, CDK1, CDK2, CHRNA5, MMP1, and MMP9. Moreover, we inputted the above targets and corresponding compounds into systemsDock for molecular docking verification. The docking scores showed that most of them had good binding activity, especially the CHRNA3-isomatrine pair (6.802), CHRNA3-baptifoline pair (6.787), CHRNA3-matrine pair (6.783), CHRNA3-sophoridine pair (6.731), and PRKCA-9α-hydroxymatrine pair (6.657). For CHRNA3 and CHRNA5, several genome-wide association studies (GWAS) have ascertained that CHRNA3 and CHRNA5 are associated with the risk of LC [72]. CHRNA3 may be a more important candidate susceptibility gene for LC. A study has shown that the CHRNA3 subunit binds to nicotine-derived nitrosamine ketone (NNK), subsequently upregulating nuclear factor-κB (NF-κB) to induce cell proliferation and increase the risk of LC [73]. For CHRNA5, a study has shown that knockdown of α5-nAChR, which is encoded by the CHRNA5 gene, could significantly mediate crucial pathways, including cell cycle distribution, apoptosis, DNA replication and pathways in cancer. Additionally, silencing α5-nAChR restrains the progression of nicotine-related NSCLC [74]. Therefore, CKI might produce therapeutic effects by inhibiting the expression of CHRNA3 and CHRNA5.

DRD2 was targeted by 3 compounds from CKI, including baptifoline, N-methylcytisine and sophocarpine. DRD2 is expressed in different pulmonary carcinoma cells [75]. Moreover, the DRD2 agonist quinpirole could counteract SCLC cell proliferation in a dose- and time-dependent manner [76]. Campa D et al. [77] indicated that DRD2 polymorphisms were related to a 2- to 5-fold increased risk of NSCLC. Thus, we deduced that the mechanism for treating LC might be associated with the activation of DRD2 by CKI. PRKCA is a serine-threonine kinase that plays a vital role in the G1 phase arrest of cancer cells [66]. A previous study has shown that the CDK2 inhibitor could elicit antineoplastic effects in LC [67]. The CDK1 gene plays an important role in the progression of cells from the G2 phase to the M phase. In addition, high expression of CDK1 is associated with poor prognosis in patients with advanced NSCLC [68]. Moreover, a study found that CDK1 was a direct target of miR-181a and that miR-181a inhibited cell proliferation by modulating CDK1 mRNA and protein levels in NSCLC cells [69]. Fortunately, our work found that CDK1 and CDK2 interact with multiple ingredients for CKI, including adenine, and macrozamin, and CKI has been shown to have therapeutic effects on cancer through inhibiting CDK2 activity [70]. In addition, matrine, the main active compound of CKI has been found to exhibit time-dependent inhibition of the expression of CDK1 in prostate cancer cells [71]. Hence, CKI might treat LC by modulating the expression of CDK1 and CDK2.

tumor development [65]. The CDK2 and cyclin A complex plays a vital role in the G1 phase arrest of cancer cells [66]. A previous study has shown that the CDK2 inhibitor could elicit antineoplastic effects in LC [67]. The CDK1 gene plays an important role in the progression of cells from the G2 phase to the M phase. In addition, high expression of CDK1 is associated with poor prognosis in patients with advanced NSCLC [68]. Moreover, a study found that CDK1 was a direct target of miR-181a and that miR-181a inhibited cell proliferation by modulating CDK1 mRNA and protein levels in NSCLC cells [69]. Fortunately, our work found that CDK1 and CDK2 interact with multiple ingredients for CKI, including adenine, and macrozamin, and CKI has been shown to have therapeutic effects on cancer through inhibiting CDK2 activity [70]. In addition, matrine, the main active compound of CKI has been found to exhibit time-dependent inhibition of the expression of CDK1 in prostate cancer cells [71]. Hence, CKI might treat LC by modulating the expression of CDK1 and CDK2.
Table 1: The docking information of 7 targets with corresponding compounds.

| Number | Target | PDBID | Compound               | CID       | Docking score |
|--------|--------|-------|------------------------|-----------|---------------|
| 1      | CHRNA3 | 4ZK4  | isomatrine             | 5271984   | 6.802         |
|        |        |       | baptifoline            | 621307    | 6.787         |
|        |        |       | matrine                | 91466     | 6.783         |
|        |        |       | sophoridine            | 165549    | 6.731         |
|        |        |       | lamprolobine           | 87752     | 6.123         |
|        |        |       | N-methylcytisine       | 670971    | 6.069         |
| 2      | DRD2   | 2HLB  | baptifoline            | 621307    | 6.616         |
|        |        |       | sophocarpine           | 115269    | 6.486         |
|        |        |       | N-methylcytisine       | 670971    | 6.370         |
| 3      | PRKCA  | 4RA4  | 9α-hydroxymatrine      | 15385684  | 6.657         |
|        |        |       | sophoranol             | 12442899  | 6.635         |
|        |        |       | adenine                | 190       | 6.058         |
| 4      | CDK1   | 5LQF  | macrozamin             | 9576780   | 6.111         |
|        |        |       | adenine                | 190       | 5.385         |
| 5      | CDK2   | 2R3I  | macrozamin             | 9576780   | 5.933         |
|        |        |       | adenine                | 190       | 5.712         |
| 6      | MMP1   | 1SU3  | adenine                | 190       | 5.508         |
|        |        |       | oxymatrine             | 114850    | 5.371         |
| 7      | MMP9   | 1ITV  | adenine                | 190       | 6.068         |
|        |        |       | matrine                | 91466     | 5.464         |

Figure 6: The detailed target-compound interactions of the docking simulation.
kinase that is associated with various cellular functions [78]. Previous studies have proven that the PRKCA gene might have multiple effects on the lung, such as peribroncholar cell proliferation and proinflammatory and profibrotic cytokine expression [79]. In addition, a study has shown that PKCa (PRKCA) is a significant protein in LC [80]. Other research has also demonstrated that PRKCA is a potential hub in LC-related signals [81]. Therefore, the mechanism of CKI for the treatment of LC may be related to its regulation of PRKCA expression. MMP1 and MMP9 are matrix metalloproteinase (MMP) genes that belong to a large family of zinc-dependent endopeptidases [82, 83]. The upregulation of MMP has been shown in various types of solid cancers [84]. A study has shown that the imbalance between MMPs and their depressors plays a significant role in the development of head and neck cancer and the prognosis of patients [85]. The expression of MMP1 is related to many diseases, including emphysema and malignant tumors [86]. A previous study demonstrated that the polymorphism MMP1 -1607 1G > 2G was significantly related to a remarkable increase in cancer risk [87]. A study by Yu et al. [88] found that the expression of MMP1 increased in the process of invasion and metastasis of NSCLC. Notably, our study showed that MMP1 was targeted by adenine and oxymatrine, and previous evidence has indicated that oxymatrine inhibits the proliferation and facilitates apoptosis of cancer cells through downregulating MMP2 and MMP9 expression [89–91]. However, the relationship among oxymatrine, MMP1, and LC cells is still unclear, which needs to be further explored. MMP9 is undetectable in healthy tissue, but during inflammation and cancer it is highly upregulated [92]. A study has indicated that MMP9 is regulated by myocardial infarction-associated transcript (MIAT) to affect the migration and invasion of NSCLC [93]. Furthermore, an existing study has found that 3T3-L1 adipocyte-derived exosomes promote murine 3LL Lewis LC cells invasion in vitro through increasing MMP9 activity [94]. The present study found that MMP9 was targeted by adenine and matrine, and several studies have shown that matrine could reduce the level of MMP9 in cancer cells [53, 95]. In addition, CKI has been proved to have the suppression action for growth and migration of LC cells by inhibiting MMP9 expression [96]. Therefore, this indicated that CKI produced the healing efficacy for LC by regulating MMP1 and MMP9 expression.

In this study, we performed a GO enrichment analysis to clarify the multiple mechanisms of CKI against LC from a systematic level. These targets were highly associated with G1/S transition of mitotic cell cycle, ERK1 and ERK2 cascade, protein phosphorylation, protein kinase activity, and ATP binding in the GO enrichment analysis. Thus, the results demonstrated that CKI mainly produces therapeutic effects by participating in these biological processes and molecular functions.

In the pathway enrichment, we found that the pathways directly associated with LC were non-small-cell lung cancer
Figure 8: KEGG analysis of potential targets. The Y-axis shows significantly enriched KEGG pathways of the target genes, and the X-axis shows the rich factor (FDR < 0.01). The rich factor represents the ratio of the number of target genes belonging to a pathway to the number of all the annotated genes located in the pathway. A higher rich factor represents a higher level of enrichment. The size of the dot indicates the number of target genes in the pathway, and the color of the dot reflects the different P value range.

(hsa05223) and small cell lung cancer (hsa05222). Histological subtypes of LC mainly included NSCLC and SCLC; approximately 85% of all LC cases are NSCLC, and 15% are SCLC [97, 98]. In addition, pathways in cancer (hsa05200) were identified as a significant pathway in LC treatment with the highest number of genes. In this pathway, the genes in the compound-LC target network were members of many vital subpathways, such as the PI3K-Akt signaling pathway. The other significantly enriched pathway was proteoglycans in cancer (hsa05205), and it also included the PI3K-Akt signaling pathway as an important subpathway. The PI3K-Akt signaling pathway (hsa04151) regulates numerous cellular functions, such as cell growth, proliferation, differentiation, survival, and invasion, and modulates the occurrence of NSCLC [99]. Moreover, the PI3K-Akt pathway is involved in cell apoptosis in multiple cell lines, such as LC cell lines [100]. A study has demonstrated that MMP9 promotes the development of LC through the PI3K-Akt signaling pathway [101]. Other research has shown that matrine regulates the expression of related genes and proteins through the PI3K-Akt signal transduction pathway to induce apoptosis in A549 cells, a LC cell line [102]. Therefore, it was speculated that the ingredients of CKI might play a significant role in treating LC through key factors in these signaling pathways.

5. Conclusions
In the present study, we found 16 compounds of CKI and predicted 180 putative targets, proving that CKI was a complex preparation with the multicomponent and multitarget features. CKI exerted treatment effects on LC by regulating 27 targets, which were mainly connected to adenine, macrozamin, matrine, oxymatrine, baptifoline, and N-methylcytisine, and 8 core targets were found through network analysis, namely CHRNA3, DRD2, PRKCA, CDK1, CDK2, CHRNA5, MMP1, and MMP9. Additionally, further molecular docking simulation confirmed that CHRNA3, DRD2, PRKCA, CDK1, CDK2, MMP1, and MMP9 had good binding affinities with the corresponding compounds. The GO enrichment analysis showed that the targets of CKI in the treatment of LC might be closely associated with certain biological processes and molecular functions, such as G1/S transition of mitotic cell cycle, positive regulation of ERK1 and ERK2 cascade, and so on. Furthermore, the KEGG pathway enrichment analysis suggested that CKI might simultaneously act on a variety of signal transduction pathways associated with the pathogenesis of LC, including pathways in cancer, proteoglycans in cancer, PI3K-Akt signaling pathway, non-small-cell lung cancer, and small cell lung cancer.
In summary, the current study employed the network pharmacology method to investigate the complex network relationship between multiple components, targets, and pathways for CKI in the treatment of LC. The results validated and predicted the molecular mechanism of CKI in LC at a system level, which might provide insight into the mechanisms of CKI and other anticancer TCMs and facilitate the widespread application of CKI in treating LC. However, the results from our research are based on computational analysis, and further experiments are needed to verify these hypotheses.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interests.

Authors’ Contributions

Ziqi Meng, Xinkui Liu, and Jiarui Wu conceived and designed the research; Wei Zhou, Shuyu Liu, and Kaihuan Wang collected and analyzed the data; Zhiwei Jing provided useful suggestions on the methodology; Ziqi Meng and Xinkui Liu wrote the paper. All authors read and approved the final version of the manuscript. Ziqi Meng and Xinkui Liu contributed equally to this work.

Acknowledgments

This work was supported by the National Nature Science Foundation of China (Grant nos. 81473547 and 81673829).

Supplementary Materials

Supplementary materials contain four tables. Supplementary Table S1: information about the 16 compounds of Compound Kushen Injection. Supplementary Table S2: 97 targets related to LC. Supplementary Table S3: the information of 26 nodes in the PPI network of LC targets. Supplementary Table S4: 27 potential targets of CKI for treating LC. (Supplementary Materials)

References

[1] J. Zhu, M. Chen, N. Chen et al., “Glycyrrhetic acid induces G1-phase cell cycle arrest in human non-small cell lung cancer cells through endoplasmic reticulum stress pathway,” International Journal of Oncology, vol. 46, no. 3, pp. 981–988, 2015.

[2] Q. Leng, Y. Lin, F. Jiang et al., “A plasma miRNA signature for lung cancer early detection,” Oncotarget, vol. 8, no. 67, pp. 111902–111911, 2017.
Evidence-Based Complementary and Alternative Medicine

[3] X. Gao, R.-X. Tang, Q.-N. Xie et al., “The clinical value of miR-193a-3p in non-small cell lung cancer and its potential molecular mechanism explored in silico using RNA-sequencing and microarray data,” FEBS Open Bio, vol. 8, no. 1, pp. 94–109, 2018.

[4] K. Politi and R. S. Herbst, “Lung cancer in the era of precision medicine,” Clinical Cancer Research, vol. 21, no. 10, pp. 2213–2220, 2015.

[5] X. B. D’Journo, P.-E. Falcoz, M. Alifano et al., “Oropharyngeal and nasopharyngeal decontamination with chlorhexidine gluconate in lung cancer surgery: a randomized clinical trial,” Intensive Care Medicine, vol. 44, no. 5, pp. 578–587, 2018.

[6] M. F. Benveniste, J. Welsh, C. Viswanathan et al., “Lung cancer: posttreatment imaging: radiation therapy and imaging findings,” Radiologic Clinics of North America, vol. 56, no. 3, pp. 471–483, 2018.

[7] F. L. Sardo, S. Strano, and G. Blandino, “YAP and TAZ in lung cancer: oncogenic role and clinical targeting,” Cancers, vol. 10, no. 5, p. E137, 2018.

[8] K. Wang, S. Shan, S. Wang, X. Gu, X. Zhou, and T. Ren, “HMGB1-containing nucleosome mediates chemotherapy-induced metastasis of human lung cancer,” Biochemical and Biophysical Research Communications, vol. 500, no. 3, pp. 758–764, 2018.

[9] W. Xu, G. Yang, Y. Xu et al., “The possibility of traditional Chinese medicine as maintenance therapy for advanced non-small cell lung cancer,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 278917, 9 pages, 2014.

[10] Y. Mao, J. Hao, Z.-Q. Jin et al., “Network pharmacology-based and clinically relevant prediction of the active ingredients and potential targets of Chinese herbs in metastatic breast cancer patients,” Oncotarget, vol. 8, no. 16, pp. 27007–27021, 2017.

[11] X. Ma, R. Li, J. Wang et al., “The therapeutic efficacy and safety of compound kushen injection combined with transarterial chemoembolization in inoperable hepatocellular carcinoma: an update systematic review and meta-analysis,” Frontiers in Pharmacology, vol. 7, article 70, 2016.

[12] L. Yu, Y. Zhou, Y. Yang, F. Lu, and Y. Fan, “Efficacy and safety of compound kushen injection on patients with advanced colon cancer: a meta-analysis of randomized controlled trials,” Evidence-Based Complementary and Alternative Medicine, vol. 2017, Article ID 7102514, 9 pages, 2017.

[13] Z. Qu, J. Cui, Y. Harata-Lee et al., “Identification of candidate anti-cancer molecular mechanisms of compound kushen injection using functional genomics,” Oncotarget, vol. 7, no. 40, pp. 66003–66019, 2016.

[14] W. Wang, R. L. You, W. J. Qin et al., “Anti-tumor activities of active ingredients in Compound Kushen Injection,” Acta Pharmacologica Sinica, vol. 36, no. 6, pp. 676–679, 2015.

[15] Z. W. Zhang, L. N. Hai, Z. Y. Gao, and J. H. Wang, “Study on rationality for compatibility of Kushen Injection,” Chinese Journal of Experimental Traditional Medical Formulae, vol. 18, no. 9, pp. 229–232, 2012 (Chinese).

[16] Y. Jin, Q. Yang, L. Liang et al., “Compound kushen injection suppresses human acute myeloid leukemia by regulating the Prdxs/ROS/Trx1 signalling pathway,” Journal of Experimental & Clinical Cancer Research, vol. 37, no. 1, article 277, 2018.

[17] L. Gao, K. Wang, Y. Zhou, J. Fang, X. Qin, and G. Du, “Uncovering the anticancer mechanism of Compound Kushen Injection against HCC by integrating quantitative analysis, network analysis and experimental validation,” Scientific Reports, vol. 8, no. 624, 2018.

[18] W. Xu, H. Lin, Y. Zhang et al., “Compound Kushen Injection suppresses human breast cancer stem-like cells by down-regulating the canonical Wnt/β-catenin pathway,” Journal of Experimental & Clinical Cancer Research, vol. 30, no. 1, article 103, 2011.

[19] H. Tu, B. Lei, S. Meng et al., “Efficacy of Compound Kushen Injection in combination with induction chemotherapy for treating adult patients newly diagnosed with acute leukemia,” Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 3121402, 7 pages, 2016.

[20] Y. W. Guo, X. Y. Zhang, and X. H. Pan, “Observation of the curative effect of Compound Kushen Injection on mild to moderate cancer pain,” The Journal of Medical Theory and Practice, no. 2, pp. 165–166, 2005.

[21] X. Y. Huang, Y. M. Guo, X. X. Sang et al., “Systematic review of Compound Kushen Injection in relieving cancer-related pain,” Chinese Journal of Experimental Traditional Medical Formulae, vol. 22, no. 2, pp. 172–179, 2016.

[22] L. Zhang, C. Wu, Y. Zhang et al., “Comparison of efficacy and toxicity of traditional chinese medicine (TCM) herbal mixture LQ and conventional chemotherapy on lung cancer metastasis and survival in mouse models,” PLoS ONE, vol. 9, no. 10, article e109814, 2014.

[23] Y. X. Zhang, X. R. Cheng, and W. X. Zhou, “Drug repositioning—the important field of network pharmacology,” Chinese Journal of Pharmacology and Toxicology, vol. 26, no. 6, pp. 779–786, 2012.

[24] J. Wang and X. J. Li, “Network pharmacology and drug discovery,” Progress in Physiological Sciences, vol. 42, no. 4, pp. 241–245, 2011.

[25] Y. Bai, X. M. Fan, H. Sun, Y. M. Wang, Q. L. Liang, and G. A. Luo, “The mechanism of rosiglitazone compound based on network pharmacology,” Acta Pharmaceutica Sinica, vol. 50, no. 3, pp. 284–290, 2015.

[26] S. Zhang, L. Shan, Q. Li et al., “Systematic analysis of the multiple bioactivities of green tea through a network pharmacology approach,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 512081, 11 pages, 2014.

[27] Y. Zhang, X. Mao, J. Su et al., “A network pharmacology-based strategy deciphers the underlying molecular mechanisms of Qixuehu Capsule in the treatment of menstrual disorders,” Chinese Medicine, vol. 12, no. 1, article 23, 2017.

[28] J. J. Zhang, J. L. Yang, and X. M. Wu, “Clinical observation of Compound Kushen Injection in the treatment of advanced non-small cell lung cancer,” Journal of New Chinese Medicine, vol. 47, no. 1, pp. 190–192, 2015.

[29] X. Y. Wu, V. C. H. Chung, P. Lu et al., “Chinese herbal medicine for improving quality of life among nonsmall cell lung cancer patients: overview of systematic reviews and network meta-analysis,” Medicine, vol. 95, no. 1, Article ID e2410, pp. 1–12, 2016.

[30] X. Q. Fan and L. K. Du, “Compound Kushen Injection in the treatment of 56 cases of advanced lung cancer,” China Foreign Medical Treatment, vol. 31, no. 11, p. 125, 2012.

[31] Y. Ma, “Study on chemical constituents and quality control of Compound Kushen Injection,” China Academy of Chinese Medical Sciences, 2012.

[32] C. Chen, H. B. Qu, R. C. Hao, M. Z. Dong, A. P. Li, and Q. Shao, “Ion - pair RP - HPLC simultaneous determination of four alkaloids in compound Kushen injection,” Chinese Journal of Pharmaceutical Analysis, vol. 32, no. 6, pp. 1006–1009, 2012.
Evidence-Based Complementary and Alternative Medicine

[33] S. Kim, P. A. Thiessen, E. E. Bolton et al., “PubChem substance and compound databases,” Nucleic Acids Research, vol. 44, no. 1, pp. D1202–D1213, 2016.

[34] D. Szklarczyk, A. Santos, C. Von Mering, L. J. Jensen, P. Bork, and M. Kuhn, “STITCH 5: Augmenting protein-chemical interaction networks with tissue and affinity data,” Nucleic Acids Research, vol. 44, no. 1, pp. D380–D384, 2016.

[35] M. Hong, S. Li, H. Y. Tan et al., “A network-based pharmacology study of the herb-induced liver injury potential of traditional hepatoprotective Chinese herbal medicines,” Molecules, vol. 22, no. 4, article no. 632, 2017.

[36] J. Nickel, B.-O. Gohlke, J. Erehman et al., “SuperPred: update on drug classification and target prediction,” Nucleic Acids Research, vol. 42, no. 1, pp. W26–W31, 2014.

[37] D. Gfeller, A. Grosdidier, M. Wirth, A. Daina, O. Michielin, and D. Gfeller, A. Grosdidier, M. Wirth, A. Daina, O. Michielin, “Evaluation of matrine derivatives containing benzo-α-pyrene structure as potent anti-lung cancer agents,” Scientific Reports, vol. 6, no. 1, Article ID 35918, 2016.

[38] J. Yang, D. He, Y. Peng et al., “Matrine suppresses the migration and invasion of NSCLC cells by inhibiting PAX2-induced epithelial-mesenchymal transition,” OncoTargets and Therapy, vol. 10, pp. 5209–5217, 2017.

[39] W. Lu, G. Wang, S. Liu et al., “Synthesis and biological evaluation of matrine derivatives containing benzo-α-pyrene structure as potent anti-lung cancer agents,” Scientific Reports, vol. 6, no. 1, Article ID 35918, 2016.

[40] S. Ham, S. Lee, K. Jeong et al., “A network pharmacology approach to uncover the pharmacological mechanism of Xiaoyao powder on osteoarthritis,” Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 3246946, 10 pages, 2016.

[41] J. S. Amberger, C. A. Bocchini, F. Schiettecatte, A. F. Scott, and A. Hamosh, “OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders,” Nucleic Acids Research, vol. 43, no. 1, pp. D789–D798, 2015.

[42] D. Szklarczyk, J. H. Morris, H. Cook et al., “The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible,” Nucleic Acids Research, vol. 45, no. 1, pp. D362–D368, 2017.

[43] M. Kohl, S. Wiese, and B. Warscheid, “Cytoscape: software for visualization and analysis of biological networks,” Methods in Molecular Biology, vol. 696, pp. 291–303, 2013.

[44] H. Liu, L. Zeng, K. Yang, and G. Zhang, “A network pharmacology approach to explore the pharmacological mechanism of Xiaoyao powder on anovulatory infertility,” Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 2960372, 13 pages, 2016.

[45] Q. Kong, Y. Ma, J. Yu, and X. Chen, “Predicted molecular targets and pathways for germacrone, curdione, and furanodienone in the treatment of breast cancer using a bioinformatics approach,” Scientific Reports, vol. 7, no. 1, Article ID 15543, 2017.

[46] K. Hsin, Y. Matsuoka, Y. Asai et al., “SystemsDock: a web server for network pharmacology-based prediction and analysis,” Nucleic Acids Research, vol. 44, no. 1, pp. W507–W513, 2016.

[47] D. W. Huang, B. T. Sherman, and R. A. Lempicki, “Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists,” Nucleic Acids Research, vol. 37, no. 1, pp. 1–13, 2009.

[48] P. W. Rose, A. Prlč, and A. Altunkaya, “he RCSB protein data bank: integrative view of protein, gene and 3D structural information,” Nucleic Acids Research, vol. 45, no. 1, pp. D271–D281, 2017.

[49] K.-Y. Hsin, S. Ghosh, and H. Kitano, “Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology,” PloS ONE, vol. 8, no. 12, Article ID e83922, 2013.

[50] B. Yanju, L. Yang, B. Hua et al., “A systematic review and meta-analysis on the use of traditional Chinese medicine compound kushen injection for bone cancer pain,” Supportive Care in Cancer, vol. 22, no. 3, pp. 825–836, 2014.

[51] Y. Guo, Y. Huang, H. Shen et al., “Efficacy of compound Kushen injection in relieving cancer-related pain: a systematic review and meta-analysis,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 840742, 8 pages, 2015.

[52] L. Wu, G. Wang, S. Liu et al., “Synthesis and biological evaluation of matrine derivatives containing benzo-α-pyrene structure as potent anti-lung cancer agents,” Scientific Reports, vol. 6, no. 1, Article ID 35918, 2016.

[53] J. Yang, D. He, Y. Peng et al., “Matrine suppresses the migration and invasion of NSCLC cells by inhibiting PAX2-induced epithelial-mesenchymal transition,” OncoTargets and Therapy, vol. 10, pp. 5209–5217, 2017.

[54] W. Lu, G. Wang, J. Wei et al., “Matrine derivative YF-18 inhibits lung cancer cell proliferation and migration through down-regulating Skp2,” Oncotarget, vol. 8, no. 7, pp. 11729–11738, 2017.

[55] B. Sun and M. Xu, “Matrine inhibits the migratory and invasive properties of nasopharyngeal carcinoma cells,” Molecular Medicine Reports, vol. 11, no. 6, pp. 4158–4164, 2015.

[56] Y. Fang, H. Ying, Y. Guo, X. Cai, M. Xu, and L. Lu, “Novel matrine derivative MD-1 attenuates hepatic fibrosis by inhibiting EGFR activation of hepatic stellate cells,” Protein & Cell, vol. 7, no. 9, pp. 662–672, 2016.

[57] X. Wang, C. Liu, J. Wang et al., “Oxymatrine inhibits the migration of human colorectal carcinoma RKO cells via inhibition of PAI-1 and the TGF-β/Smad signaling pathway,” Oncology Reports, vol. 37, no. 2, pp. 747–753, 2017.

[58] J. Wu, Y. Cai, M. Li, Y. Zhang, H. Li, and Z. Tan, “Oxymatrine promotes S-phase arrest and inhibits cell proliferation of human breast cancer cells in vitro through mitochondria-mediated apoptosis,” Biological & Pharmaceutical Bulletin, vol. 40, no. 8, pp. 1232–1239, 2017.

[59] Y. J. Zhou, Y. J. Guo, X. L. Yang, and Z. L. Ou, “Anti-cervical cancer role of matrine, oxymatrine and sophora flavescens alkaloid gels and its mechanism,” Journal of Cancer, vol. 9, no. 8, pp. 1357–1364, 2018.

[60] W. Li, X. Yu, S. Tan, W. Liu, L. Zhou, and H. Liu, “Oxymatrine inhibits non–small cell lung cancer via suppression of EGFR signaling pathway,” Cancer Medicine, vol. 7, no. 1, pp. 208–218, 2018.

[61] H. G. Fan, L. T. Li, X. J. Zhang et al., “Oxymatrine Downregulates TLR4, TLR2, MyD88, and NF-κB and protects rat brains against focal ischemia,” Mediators of Inflammation, vol. 2009, Article ID 704706, 10 pages, 2009.

[62] X. Bian, J.-Q. Wu, and X.-J. Nie, “Effects of oxymatrine on the expressions of pro-collagen and fibronectin of fibroblasts derived from human hyperplastic scars,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 32, no. 10, pp. 1390–1393, 2012.

[63] M. Bao, Y. J. Song, J. J. Xia, P. L. Li, Q. Liu, and Z. R. Wan, “MiR-1269 promotes cell survival and proliferation by targeting tp53 and caspase-9 in lung cancer,” Oncotarget, vol. 11, pp. 1721–1732, 2018.

[64] J. Gu, Y. Zhou, L. Huang et al., “TP53 mutation is associated with a poor clinical outcome for non–small cell lung cancer: Evidence from a meta-analysis,” Molecular and Clinical Oncology, vol. 5, no. 6, pp. 705–713, 2016.

[65] Y. Wang, T. Chen, H. Huang et al., “miR-363-3p inhibits tumor growth by targeting PCNA in lung adenocarcinoma,” Oncotarget, vol. 8, no. 12, pp. 20133–20144, 2017.
[64] Y.-C. Chen, M.-C. Lin, C.-C. Hsiao et al., “Increased S100A15 expression and decreased DNA methylation of its gene promoter are involved in high metastasis potential and poor outcome of lung adenocarcinoma,” Oncotarget, vol. 8, no. 28, pp. 45710–45724, 2017.

[65] J. S. M. Richardson, N. Aminudin, and S. N. A. Malek, “Chalepin: a compound from Ruta angustifolia L. pers exhibits cell cycle arrest at S phase, suppresses nuclear factor-kappa B (NF-κB) pathway, signal transducer and activation of transcription 3 (STAT3) phosphorylation and extrinsic apoptotic pathway in non-small cell lung cancer carcinoma (A549),” Pharmacognosy Magazine, vol. 13, no. 51, pp. S489–S498, 2017.

[66] L. Zhou, F. Wu, W. Jin et al., “Theabrownin inhibits cell cycle progression and tumor growth of lung carcinoma through c-myc-related mechanism,” Frontiers in Pharmacology, vol. 8, article 75, 2017.

[67] M. Kawakami, L. M. Mustachio, J. Rodriguez-Canales et al., “Next-generation CDK2/9 inhibitors and anaphase catastrophe in lung cancer,” JNCI: Journal of the National Cancer Institute, vol. 109, no. 6, Article ID djuw297, 2017.

[68] J. Wang, Y. Zhang, S. Xu et al., “Prognostic significance of G2/M arrest signaling pathway proteins in advanced non-small cell lung cancer patients,” Oncology Letters, vol. 9, no. 3, pp. 1266–1272, 2015.

[69] Q. Shi, Z. Zhou, N. Ye, Q. Chen, X. Zheng, and M. Fang, “MiR-181a inhibits non-small cell lung cancer cell proliferation by targeting CDK1,” Cancer Biomarkers, vol. 20, no. 4, pp. 539–546, 2017.

[70] L. Chen, Y. G. Feng, C. Yu et al., “Clinical effect of using of Chinese herba preparation qiling combined with Fu Fang Ku Shen injection for the patients with advanced prostate cancer,” Lianoning Journal of Traditional Chinese Medicine, vol. 44, no. 7, pp. 1451–1453, 2017.

[71] J. Chang, S. Hu, W. Wang et al., “Matrine inhibits prostate cancer via activation of the unfolded protein response/endoplasmic reticulum stress signaling and reversal of epithelial to mesenchymal transition,” Molecular Medicine Reports, vol. 18, no. 1, pp. 945–957, 2018.

[72] A. Bordas, J. L. Cedillo, F. Arnalich et al., “Expression patterns for nicotinic acetylcholine receptor subunit genes in smoking-related lung cancers,” Oncotarget, vol. 8, no. 40, pp. 67878–67890, 2017.

[73] C. I. Amos, X. Wu, P. Broderick et al., “Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1,” Nature Genetics, vol. 40, no. 5, pp. 616–622, 2008.

[74] H. Sun, Y. Jia, and X. Ma, “Alpha5 nicotinic acetylcholine receptor contributes to nicotine-induced lung cancer development and progression,” Frontiers in Pharmacology, vol. 8, article 573, 2017.

[75] M. Sheikhpour, G. Ahangari, M. Sadeghizadeh, and A. Deezagi, “A novel report of apoptosis in human lung carcinoma cells using selective agonist of D2-like dopamine receptors: a new approach for the treatment of human non-small cell lung cancer,” International Journal of Immunopathology and Pharmacology, vol. 26, no. 2, pp. 393–402, 2013.

[76] E. Cherubini, A. Di Napoli, A. Noto et al., “Genetic and functional analysis of polymorphisms in the human dopamine receptor and transporter genes in small cell lung cancer,” Journal of Cellular Physiology, vol. 231, no. 2, pp. 345–356, 2016.

[77] D. Campa, S. Zienoldddiny, H. Lind et al., “Polymorphisms of dopamine receptor/transporter genes and risk of non-small cell lung cancer,” Lung Cancer, vol. 56, no. 1, pp. 17–23, 2007.

[78] A. Bahrami, S. Lee, G. Wu et al., “Pigment-synthesizing melanocytic neoplasm With Protein Kinase C Alpha (PKRCA) fusion,” JAMA Dermatology, vol. 152, no. 3, pp. 318–322, 2016.

[79] J. Du and L. Zhang, “Pathway deviation-based biomarker and multi-effect target identification in asbestos-related squamous cell carcinoma of the lung,” International Journal of Molecular Medicine, vol. 39, no. 3, pp. 579–586, 2017.

[80] C. Wang, X. Wang, H. Liang et al., “miR-203 inhibits cell proliferation and migration of lung cancer cells by targeting PKCα,” PLoS ONE, vol. 8, no. 9, Article ID e73985, 2013.

[81] S. A. El-Aarag, A. Mahmoud, M. H. Hashem, H. Abd Eldaker, A. E. Hemeida, and M. ElHefnawi, "In silico identification of potential key regulatory factors in smoking-induced lung cancer," BMC Medical Genomics, vol. 10, no. 1, article 40, 2017.

[82] Y. Akiyama, Y. Koda, S.-J. Byeon et al., “Reduced expression of SET7/9, a histone mono-methyltransferase, is associated with gastric cancer progression,” Oncotarget, vol. 7, no. 4, pp. 3966–3983, 2016.

[83] A. Sakowicz, M. Lisowska, L. Biesiada et al., “Association of maternal and fetal single-nucleotide polymorphisms in metalloproteinase (MMP1, MMP2, MMP3, and MMP9) genes with preeclampsia,” Disease Markers, vol. 2018, Article ID 1371425, 2018.

[84] T. C. Shen, W. S. Chang, C. W. Tsai et al., “The contribution of matrix metalloproteinase-1 promoter genotypes in Taiwan lung cancer risk,” Anticancer Research, vol. 38, no. 1, pp. 253–257, 2018.

[85] W. Pietruszewska, K. Bojanowska-Po´zniak, and J. Kobos, “Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: An immunohistochemical study,” Otolaryngologia Polska, vol. 70, no. 3, pp. 32–43, 2016.

[86] P. I. Carver, V. Anguiano, J. M. D’Armiento, and T. Shiomi, “Mmp1a and Mmp1b are not functional orthologs to human MMP1 in cigarette smoke induced lung disease,” Experimental and Toxicologic Pathology, vol. 67, no. 2, pp. 153–159, 2015.

[87] L. Lu, Y. Sun, Y. Li, and P. Wan, “The polymorphism MMP1 –1607 (1G −2G) is associated with a significantly increased risk of cancers from a meta-analysis,” Tumor Biology, vol. 36, no. 3, pp. 1685–1693, 2015.

[88] H. Yu, X. W. Ye, Z. F. Wang, W. J. Liu, M. Lin, and X. Y. Zhang, “Clinical significance of Sna1l and MMP-1 expression in non-small cell lung cancer,” Chongqing Medicine, vol. 41, no. 28, pp. 2919–2921, 2012.

[89] J. Li, K. Jiang, and F. Zhao, “Oxymatrine suppresses proliferation and facilitates apoptosis of human ovarian cancer cells through upregulating miRNA-29b and downregulating matrix metalloproteinase-2 expression,” Molecular Medicine Reports, vol. 12, no. 4, pp. 5369–5374, 2015.

[90] N. Deng, L. Xie, Y. Li, H. Lin, and R. Luo, “Oxymatrine alleviates periodontitis in rats by inhibiting inflammatory factor secretion and regulating MMPs/TIMP protein expression,” Acta Cirurgica Brasileira, vol. 33, no. II, pp. 945–953, 2018.

[91] L. Qian, X. Li, P. Ye et al., “Oxymatrine induces apoptosis and inhibits invasion in Gallbladder carcinoma via PTEN/PI3K/AKT pathway,” Cytotechnology, vol. 70, no. 1, pp. 83–94, 2018.

[92] A. Pujada, L. Walter, A. Patel et al., “Matrix metalloproteinase MMP9 maintains epithelial barrier function and preserves

Evidence-Based Complementary and Alternative Medicine
mucosal lining in colitis associated cancer,” Oncotarget, vol. 8, no. 55, pp. 94650–94665, 2017.

[93] I.-L. Lai, C.-A. Yang, P.-C. Lin et al., "Long noncoding RNA MIAT promotes non-small cell lung cancer proliferation and metastasis through MMP9 activation,” Oncotarget, vol. 8, no. 58, pp. 98148–98162, 2017.

[94] J. Wang, Y. Wu, J. Guo, X. Fei, L. Yu, and S. Ma, "Adipocyte-derived exosomes promote lung cancer metastasis by increasing MMP9 activity via transferring MMP3 to lung cancer cells,” Oncotarget, vol. 8, no. 47, pp. 81880–81891, 2017.

[95] H. Huang, T. Du, G. Xu et al., "Matrine suppresses invasion of castration-resistant prostate cancer cells by downregulating MMP-2/9 via NF-κB signaling pathway,” International Journal of Oncology, vol. 50, no. 2, pp. 640–648, 2017.

[96] L. Lai, C. L. Zhai, L. J. Yanget al., "Inhibitory effect of compound Sophora flavescens injection on transplanted tumor of lung cancer in nude mice and the influence of the expression of MMP-9 and VEGF,” Chinese Medicine Science and Technology, vol. 20, no. 1, pp. 21-22, 2013.

[97] L. P. Wang, "Current situation and prospect of lung cancer immunotherapy,” Journal of Chinese Practical Diagnosis and Therapy, vol. 31, no. 2, pp. 105–110, 2017.

[98] C. J. C. D. S. Fernandes, “Evolution in the management of non-small cell lung cancer in Brazil,” Jornal Brasileiro de Pneumologia, vol. 43, no. 6, pp. 403–404, 2017.

[99] C. Pérez-Ramírez, M. Canadas-Garre, M. Á. Molina, M. J. Faus-Dáder, and M. Á. Calleja-Hernández, “PTEN and PI3K/AKT in non-small-cell lung cancer,” Pharmacogenomics, vol. 16, no. 16, pp. 1843–1862, 2015.

[100] N. Tuya, Y. Wang, L. Tong, W. Gao, R. Yu, and L. Xue, “Trichosanthin enhances the antitumor effect of gemcitabine in non-small cell lung cancer via inhibition of the PI3K/AKT pathway,” Experimental and Therapeutic Medicine, vol. 14, no. 6, pp. 5767–5772, 2017.

[101] H. Zheng and J.-F. Liu, “Studies on the relationship between PI3K/AKT signal pathway-mediated MMP-9 gene and lung cancer,” European Review for Medical and Pharmacological Sciences, vol. 21, no. 4, pp. 753–759, 2017.

[102] X. W. Zhang, C. B. Cui, P. P. Zhang et al., “Study on the mechanism of apoptosis induction of lung cancer A549 cells by matrine through PI3K/Akt signaling pathway,” Journal of Traditional Chinese Medicine, vol. 10, no. 8, pp. 821–824, 2017.